Switching Skin Cell Phenotypes: Signatures of Pharmacosensitivity to Methotrexate and Adalimumab Treatment in Psoriasis
Аннотация
Abstract Psoriasis systemic therapy personalization remains challenging. Despite the availability of effective treatments such as cytostatics and targeted biological agents, a significant proportion of patients do not achieve a satisfactory response to treatment. Besides, systemic therapy is accompanied by serious side effects, is long lasting and expensive. The present study is dedicated to identify the molecular determinants of methotrexate (MTX) and adalimumab (ADA) effectiveness in psoriasis. The main goal of the study was to perform the analysis whole transcriptome sequencing data of lesional skin compared with unaffected skin in patients with psoriasis, performed before the start of systemic treatment, followed by bioinformatic data analysis. Sensitivity to MTX was found to be associated with increased expression of genes involved in keratinocyte proliferation and IL-17-mediated inflammation. At the same time, the response to ADA correlated with alterations in the genes expression of epidermal differentiation and genes related to skin barrier function. In addition, a combination of three genes, ARG1 , IFI6 , and HAL , was identified as overexpressed in psoriatic lesions in patients with a positive treatment effect for both agents. Functional analysis suggests that this signature reflects a special phenotype of skin cells in the psoriatic lesions, combining signs of an activated interferon response, reparative potential, and arginine and histidine-associated metabolic pathways. The data obtained demonstrate that the effectiveness of therapy is determined not only by the intensity of inflammation, but also by the individual characteristics of the biochemical, metabolic and reparative features of the skin. This results highlight the possibilities for using a set of predictive genes for developing a diagnostic panel to predict treatment efficacy, and also point out new molecular mechanisms and therapeutic targets in psoriasis.